October 20, 2011 (Amsterdam, the Netherlands) — A new investigation finds that 6 years after diagnosis, brain volumes and, particularly, cognition were more severely affected in men with multiple ...

Vascular comorbidities, including diabetes and hypertension, are linked to significantly lower measures of neurologic function in people with multiple sclerosis (MS) vs patients without these ...

After menopause, women with multiple sclerosis experienced accelerated volume loss in global gray matter, the left hippocampus, and the left anterior cingulate, highlighting the menopausal transition ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

A new clinical trial for the drug ibudilast offers much-needed hope for people living with multiple sclerosis — a neurological condition that affects primarily women and has limited treatment options.

"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, suggests positron emission tomography (PET) brain scans could reveal hidden inflammation ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, data show.